Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of melatonin for insomnia.
Neurim Pharmaceuticals is an Israeli company focused on CNS, with a second office in Switzerland. Could you start by introducing the company to our international readers?
"It is particularly challenging to ensure that products actually improve sleep without impairing next day performance within the insomnia market. This is one of Circadin's major strengths."
